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ORIGINAL
RESEARCH
M.T. Luetmer
D.F. Kallmes

Have Referral Patterns for Vertebroplasty
Changed since Publication of the PlaceboControlled Trials?
BACKGROUND AND PURPOSE: Our aim was to determine whether referral patterns and rates of

vertebroplasties at the Mayo Clinic have changed after the publication of the INVEST and the Australian
Trial. In August of 2009, we performed a retrospective review of patients undergoing vertebroplasties
and those patients who were referred for but did not receive vertebroplasties before and after the
recently published placebo-controlled vertebroplasty trials.
MATERIALS AND METHODS: After approval by our local institutional review board, we retrospectively
evaluated all patients referred for vertebroplasty between January 5, 2004, and June 2, 2010. We
catalogued age, sex, number of treated vertebrae, physician referring the patient for vertebroplasty,
and the referring department. We calculated the mean number of referrals per month before and after
August 2009, which was the month of publication for both trials. We also calculated rates for specific
referring physician types.
RESULTS: During the full study, 1188 patients were referred, of whom 807 underwent treatment at
1378 levels for a total of 943 separate vertebroplasty procedures. The mean number of vertebroplasty
referrals per month has dropped significantly from 18.9 6 5.3 (95% CI, 17.7–20.2) before publication
to 11.3 6 3.1 (95% CI, 9.1–13.5) referrals per month after publication (P 5 .0001). Before publication,
67.3 6 14.0% (95% CI, 64.0%–70.7%) of patients referred for vertebroplasty underwent vertebroplasty, compared with 76.0 6 14.9% (95% CI, 65.4%– 86.6%) after publication (P 5 .11).
CONCLUSIONS: The number of vertebroplasty referrals at our center has decreased significantly since

the publication of INVEST and the Australian Trial, yet we continue to offer the procedure to a high
proportion of referred patients.
ABBREVIATIONS: CI 5 confidence interval; INVEST 5 INvestigational Vertebroplasty Efficacy and

Safety Trial; PMR 5 Physical Medicine and Rehabilitation
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Materials and Methods
The study was approved by our local institutional review board. This
retrospective study compared the number of patients who were evaluated for vertebroplasty and those treated with vertebroplasty before
the publication of INVEST6 and the Australian Trial, between January
5, 2004, and August 6, 2009, with the number of patients evaluated
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and treated after the publication from August 7, 2009, to June 2, 2010.
Patients included were those who were referred for vertebroplasty
and/or received $1 vertebroplasty between January 5, 2004, and June
2, 2010. Patients enrolled in research trials were included. A single
investigator (M.T.L.) performed a chart review of patient and procedure records to evaluate age, sex, number of treated vertebrae, physician referring the patient for vertebroplasty, and the referring department. Both the evaluations leading to vertebroplasty and those not
leading to vertebroplasty were grouped into months by evaluation
date. A number of previous case series from our institution have been
published by using some portions of this same patient data base.4,6
However, we have never previously performed a detailed analysis of
referral patterns and rates of vertebroplasty.

Statistical Analysis
We compared the mean number of total referrals per month and the
mean number of referrals per month by department by using the
Student t test. We divided the number of patients treated with vertebroplasty by the total number of those referred for vertebroplasty
evaluation, and these ratios were compared pre- and post-INVEST by
using the Student t test.

Results
A total of 1188 patients underwent 1382 vertebroplasty evaluations during the entire study period. Eight hundred seven
(68%) of 1188 referred patients underwent treatment at 1378
vertebral levels in 943 separate vertebroplasty sessions. Six
hundred eighty-nine (85.4%) of 807 treated patients had 1
vertebroplasty session, 85 (10.5%) of 807 treated patients had
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ince the development of spine augmentation, there has
been a rapid rise in the use of vertebroplasty in the United
States. Vertebroplasty and kyphoplasty combined have increased 12,900% from 1993 to 2004, and rates of vertebroplasty in Medicare enrollees nearly doubled from 2001 to
2005.1,2 Furthermore, the procedure was endorsed in 2007 by
several American neurologic surgical and radiologic societies
that deemed it to be a safe and effective treatment of osteoporotic and neoplastic vertebral fractures.3
Recent blinded placebo-controlled trials have cast doubt on
the efficacy of vertebroplasty.4,5 Whether these publications have
influenced the practice of vertebroplasty remains unknown. The
purpose of this study was to determine whether referral patterns
and rates of vertebroplasties at the Mayo Clinic have changed
since publication of the placebo-controlled trials.

Mean number of referrals per month from referring departments before and after publication of INVEST and the Australian Trial
Referring
Department
Spine Center and PMR
Hematology
Orthopedics

Mean No. of Referrals per Month before
Publication
6.3 6 2.8,
95% CI, 5.7–7.0
2.2 6 1.6,
95% CI, 1.8–2.6
1.6 6 1.4,
95% CI, 1.3–2.0

2 vertebroplasty sessions, 20 (2.5%) of 807 treated patients had
3 vertebroplasty sessions, and 13 (1.6%) of 807 treated patients
had $4 total vertebroplasty sessions (including those before
January 5, 2004). The mean number of levels treated per session was 1.5 6 0.8; median, 1 level; range, 1– 6 levels. Of those
807 patients undergoing vertebroplasty, 516 (64%) were
women with a mean age of 74.6 6 11.7 years; median, 77 years;
range, 23–96 years. Two hundred ninety-one (36%) were
men, with a mean age of 71.3 6 13.0 years; median, 74.0 years;
range, 32–97 years. Age was at the time of the first vertebroplasty. Of those 381 patients evaluated for but not receiving
vertebroplasty, 221 (58%) were women, with mean age of
73.5 6 13.0 years; median, 76 years; range, 31–96 years. One
hundred sixty (42%) of 381 were men, with mean age of
67.5 6 13.7 years; median, 70 years; range, 22–97 years. The
age was at the time of the first evaluation.
The mean number of vertebroplasty referrals per month
dropped significantly from 18.9 6 5.3 (95% CI, 17.7–20.2)
before publication of INVEST to 11.3 6 3.1 (95% CI, 9.1–
13.5) referrals per month after publication (P 5 .0001). Before
publication, 67.3 6 14.0% (95% CI, 64.0%–70.7%) of patients
referred for vertebroplasty were offered vertebroplasty, compared with 76.0 6 14.9% (95% CI, 65.4%– 86.6%) after publication (P 5 .1083).
Referrals were received from .20 different departments
and 420 different referring physicians. The mean number of
referrals per month from the Spine Center and PMR and Orthopedics decreased significantly after the publication (Table).
There was no statistically significant difference between the
mean number of referrals from the Department of Hematology per month before and after the publication.
Discussion
In the current study, we found that at our single center, the
number of patients referred for consideration of vertebroplasty decreased significantly after the publication of INVEST
and the Australian Trial, compared with the rate of such referrals during the 5 years preceding publication of that trial.
While we have not specifically queried any referring physicians regarding reasons for changing referral patterns, we believe that the relatively sudden drop in the rate of referral reflects a response to the results published in the placebocontrolled trials. Notably, we continue to offer vertebroplasty
to a high proportion of referred patients, indicating that our
own belief in the efficacy of the procedure outweighs its risks.
The rate of referrals from the Department of Hematology,
most for patients with multiple myeloma, did not change after
publication of INVEST and the Australian Trial. Because the
INVEST trial specifically excluded patients with myeloma, re-
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Mean No. of Referrals per Month after
Publication
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3.4 6 1.3,
95% CI, 2.4–4.4
2.6 6 1.9,
95% CI, 1.2–4.0
0.6 6 1.0,
95% CI, 20.1–1.3

P
Value
.0001
.564
.0099

ferring hematologists may believe that the results of the trial
do not apply to these types of patients.
Numerous commentaries and editorials have questioned
the efficacy of spine augmentation in light of the placebocontrolled trials.7-12 Even in light of the trials and commentaries, we continue to perform vertebroplasty relatively frequently. Indeed, we noted in the current study a trend toward
an increase in the proportion of referred patients who undergo
the procedure. This increase in the percentage of referrals
leading to vertebroplasty may indicate that physicians are
more stringent than previously regarding whom they refer for
vertebroplasty.
Conclusions
The number of vertebroplasty referrals has decreased nearly
50% since the publication of INVEST and the Australian Trial,
yet we continue to offer the procedure to a high percentage of
referred patients.
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